Core Viewpoint - CG Oncology, Inc. has announced a public offering of 8,000,000 shares of common stock priced at 204.4 million in gross proceeds before expenses [1]. Company Overview - CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for bladder cancer patients [5]. Offering Details - The offering consists of 7,300,000 shares offered by CG Oncology and 700,000 shares by an existing stockholder, with the offering expected to close on December 16, 2024, subject to customary closing conditions [1]. - The underwriters have a 30-day option to purchase an additional 1,200,000 shares at the public offering price [1]. - The registration statement for the offering was filed with the Securities and Exchange Commission and declared effective on December 12, 2024 [3]. Underwriters - Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, TD Cowen, and Stifel, Nicolaus & Company are acting as joint book-running managers for the offering, with LifeSci Capital LLC as the lead manager [2].
CG Oncology Announces Pricing of Public Offering